For the quarter ending 2025-09-30, ADCT has $289,758K in assets. $527,941K in debts. $234,738K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 234,738 | 264,560 | ||
| Accounts receivable, net | 22,918 | 26,184 | ||
| Inventory | 18,042 | 17,763 | ||
| Prepaid expenses | 5,928 | 4,584 | ||
| Other current assets | 5,523 | 5,664 | ||
| Total current assets | 287,149 | 318,755 | ||
| Property and equipment, net | 0 | 1 | ||
| Operating lease right-of-use assets | 1,393 | 1,488 | ||
| Other long-term assets | 1,216 | 1,317 | ||
| Total assets | 289,758 | 321,561 | ||
| Accounts payable | 8,119 | 9,616 | ||
| Accrued expenses and other current liabilities | 53,925 | 54,984 | ||
| Total current liabilities | 62,044 | 64,600 | ||
| Deferred royalty obligation, long-term | 340,170 | 333,244 | ||
| Senior secured term loans | 115,206 | 114,473 | ||
| Operating lease liabilities, long-term | 1,127 | 1,258 | ||
| Other long-term liabilities | 9,394 | 7,170 | ||
| Total liabilities | 527,941 | 520,745 | ||
| Common shares, at chf 0.08 par value issued shares 99,453,858 at june 30, 2024 and 89,041,946 december 31, 2023 outstanding shares 96,469,641 at june 30, 2024 and 82,293,137 at december 31, 2023 | 9,763 | 9,753 | ||
| Additional paid-in capital | 1,382,493 | 1,380,224 | ||
| Treasury shares | 205 | 207 | ||
| Accumulated other comprehensive loss | -702 | -388 | ||
| Accumulated deficit | -1,629,532 | -1,588,566 | ||
| Total shareholders (deficit) equity | -238,183 | -199,184 | ||
| Total liabilities and shareholders (deficit) equity | 289,758 | 321,561 | ||
ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (ADCT)